Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02292225
Title IPI-145 With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Infinity Pharmaceuticals, Inc.
Age Groups: adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
La Jolla California 92093 United States Details
Boston Massachusetts 02115 United States Details
Hackensack New Jersey 07601 United States Details
New Hyde Park New York 11042 United States Details
Columbus Ohio 43210 United States Details
Houston Texas 77030 United States Details
Montreal Quebec H3T 1E2 Canada Details
*Shaded cells indicate that there was no data available from for the field